In comparison of other studies in human subjects, a clinical trial reported that 320 mg daily anthocyanin supplementation significantly decreased NLRP3 inflammasome-related markers (caspase-1, IL-1β, and IL-18) in PBMCs and plasma of NAFLD patients [73]. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.